How Semax Reaches the Brain Through Your Nose
Semax
0.093% brain penetration
In rat studies, 0.093% of intranasally administered semax reached brain tissue within 2 minutes, roughly 9x the penetration achieved through intravenous delivery.
Shevchenko et al., Russian Journal of Bioorganic Chemistry, 2006
Shevchenko et al., Russian Journal of Bioorganic Chemistry, 2006
View as imageSemax is a seven-amino-acid peptide. Peptides this size do not cross the blood-brain barrier efficiently when injected intravenously. They get degraded by enzymes in the blood, filtered by the kidneys, and largely excluded by the tight junctions that protect the brain from circulating molecules. Yet semax produces measurable effects on brain neurotrophic factors, gene expression, and functional connectivity when sprayed into the nose. The question is how.
The answer involves a set of anatomical shortcuts that connect the nasal cavity directly to the central nervous system. When semax is delivered as a nasal spray, it does not need to enter the bloodstream and cross the blood-brain barrier. It travels along nerve pathways that physically connect the nose to the brain, arriving in brain tissue within minutes of administration.[1]
Key Takeaways
- Radiotracer studies in rats showed 0.093% of intranasally administered semax per gram of brain tissue within 2 minutes, compared to 0.01% via intravenous delivery
- 80% of the radioactivity detected in brain tissue was intact semax, not metabolites, indicating the peptide survives the nose-to-brain transit largely undegraded
- Two nerve pathways deliver nasally administered peptides to the brain: the olfactory nerve (to the olfactory bulb and forebrain) and the trigeminal nerve (to the brainstem and wider CNS)
- Intranasal semax was more potent for cognitive improvement in animal models than the same dose given by intraperitoneal injection
- The Pro-Gly-Pro tail added to ACTH(4-10) to create semax was specifically designed to resist enzymatic degradation during transit
- Semax's nasal delivery approach is part of a broader research field exploring nose-to-brain transport for peptides too large or fragile for oral dosing
The Pharmacokinetics: What Radiotracer Studies Measured
The most direct evidence for semax's brain penetration comes from a 2006 study by Shevchenko and colleagues at the Institute of Molecular Genetics in Moscow. The team used tritium-labeled semax (radioactively tagged so its location could be tracked) and administered it intranasally to rats.
Within 2 minutes of nasal administration, 0.093% of the total administered radioactivity per gram was detected in brain tissue. That number sounds small, but context matters: when the same group measured intravenous delivery in rats, only about 0.01% per gram reached the brain within one minute. Intranasal delivery achieved roughly 9 times greater brain penetration than the intravenous route.
The composition of what reached the brain was equally important. Of the total radioactivity in brain tissue, 80% belonged to intact semax. The remaining 20% consisted of metabolites, primarily the tripeptide Pro-Gly-Pro. This means the peptide was not simply being broken down in the nose and having fragments wash into the brain. The intact, biologically active molecule was reaching brain tissue.
The study also tracked semax in blood after intranasal administration. Semax appeared in blood rapidly, confirming that some absorption occurs through the nasal mucosa into systemic circulation. But the brain concentrations were disproportionately high relative to blood levels, supporting direct nose-to-brain transport rather than blood-mediated delivery alone.
Two Highways From Nose to Brain
The nasal cavity has a unique anatomical feature that no other body surface shares: it is directly innervated by cranial nerves whose cell bodies sit inside the brain. Two nerve pathways are responsible for nose-to-brain peptide transport.[2]
The olfactory pathway
The olfactory epithelium sits in the upper nasal cavity. Olfactory receptor neurons have their cell bodies embedded in this epithelium, with axons that pass through the cribriform plate (a thin bone at the skull base) and terminate directly in the olfactory bulb. This creates a physical conduit from the nasal surface to the brain.
Peptides deposited on the olfactory epithelium can travel along these axons through two mechanisms. Intracellular transport involves the peptide being taken up by the neuron (via endocytosis or passive diffusion) and transported along the axon to the olfactory bulb. Extracellular transport involves the peptide moving through the perineural space, the fluid-filled channels surrounding the nerve fibers, without entering the cells themselves.
Extracellular transport is faster. It can deliver molecules to the brain within minutes, which matches the 2-minute timeline observed for semax. Intracellular axonal transport is slower, operating on a timescale of hours, and likely contributes to sustained brain levels rather than the initial rapid delivery.
The trigeminal pathway
The trigeminal nerve (cranial nerve V) innervates the respiratory epithelium of the nasal cavity, which covers a much larger surface area than the olfactory epithelium. Trigeminal nerve branches terminate in the brainstem (specifically the pons), providing a second direct route from nose to brain.
The trigeminal pathway delivers peptides to different brain regions than the olfactory pathway. While olfactory transport targets the forebrain (olfactory bulb, frontal cortex, hippocampus), trigeminal transport reaches the brainstem and from there can distribute more broadly through cerebrospinal fluid circulation.[3]
For semax, which has documented effects on both cortical regions (default mode network changes)[4] and subcortical areas, both pathways likely contribute. The general science of nose-to-brain transport and intranasal peptide delivery applies to many peptide compounds beyond semax.
Why Semax Was Designed for Nasal Delivery
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of the ACTH(4-10) fragment. The natural ACTH(4-10) sequence (Met-Glu-His-Phe-Arg-Trp-Gly) has neurotrophic activity but is rapidly degraded by peptidases. The key modification in semax was replacing the C-terminal amino acids with a Pro-Gly-Pro tripeptide.
This Pro-Gly-Pro tail serves two purposes. First, it dramatically increases resistance to enzymatic degradation. Proline residues create structural kinks in the peptide chain that make it a poor substrate for most exopeptidases and many endopeptidases. The 80% intact semax detected in brain tissue after nasal delivery reflects this engineered stability.
Second, the Pro-Gly-Pro sequence may itself have biological activity. The Shevchenko kinetics study found Pro-Gly-Pro as the predominant metabolite in brain tissue, and separate research on glyprolines (the family of Pro-containing peptides) suggests they have independent immunomodulatory and neuroprotective properties.[5]
The Russian formulation uses a 0.1% or 1% aqueous solution administered as nasal drops. The 0.1% concentration is the standard nootropic formulation; the 1% concentration was developed for acute neurological conditions like stroke. Both achieve the same nose-to-brain delivery mechanism; the higher concentration simply delivers more peptide per application.
What Happens After Semax Reaches the Brain
Once in brain tissue, semax triggers a cascade of molecular effects that have been documented across multiple studies.
BDNF upregulation. Dolotov and colleagues (2003, 2006) showed that intranasal semax increased brain-derived neurotrophic factor (BDNF) expression in multiple brain regions, including the hippocampus, frontal cortex, and basal forebrain.[6][7] BDNF is critical for neuronal survival, synaptic plasticity, and memory formation. The semax-induced BDNF increase was accompanied by upregulation of TrkB, the receptor through which BDNF signals.
Dopamine and serotonin modulation. Eremin and colleagues (2005) demonstrated that semax activates both dopaminergic and serotonergic systems in the brain, with effects on dopamine synthesis, turnover, and receptor activity.[8] These effects are consistent with semax's reported cognitive and mood effects.
Default mode network changes. Lebedeva and colleagues (2018) used functional MRI to show that intranasal semax altered activity in the brain's default mode network in healthy volunteers, providing direct neuroimaging evidence that the peptide reaches functionally relevant brain circuits after nasal administration.[4] This study, along with the broader connectomic analysis by Panikratova and colleagues (2020), represents the most direct evidence in humans that nasally delivered semax produces measurable brain effects.[9]
Neuroprotection in ischemia. Romanova and colleagues (2006) showed intranasal semax had neuroprotective and antiamnesic effects in a rat model of ischemic brain infarction, reducing both tissue damage and cognitive deficits.[10] The 1% formulation was developed specifically for this indication.
Intranasal vs. Injected: Why Route Matters
A study comparing intranasal and intraperitoneal semax administration found that intranasal delivery was more potent for improving learning in animal models than the same dose given by injection. This is counterintuitive: injection delivers 100% of the dose to the bloodstream, while nasal delivery loses much of the dose to mucociliary clearance, swallowing, and local degradation.
The explanation is that intranasal delivery concentrates the peptide in brain tissue. When semax is injected, most of the dose circulates systemically, gets metabolized by peripheral enzymes, and only a tiny fraction crosses the blood-brain barrier. When delivered nasally, a smaller total amount reaches the brain, but it arrives via direct neural pathways, bypassing the systemic losses entirely.
This route-dependent potency difference has practical implications. It means lower total doses can achieve brain-level effects when delivered nasally, which reduces peripheral exposure and potential off-target effects. It also explains why the Russian clinical formulations for both semax for stroke and semax for cognitive enhancement use nasal delivery rather than injection.
Limitations of the Delivery Data
The pharmacokinetic evidence for semax's nose-to-brain delivery, while compelling, has real limitations.
Single species. The radiotracer kinetics data comes from rats. Rat nasal anatomy differs from human anatomy in ways that matter for nose-to-brain delivery. Rats have proportionally larger olfactory epithelium relative to total nasal surface area. Human olfactory epithelium occupies only about 3-8% of the nasal cavity, compared to roughly 50% in rats. This means the olfactory pathway may contribute proportionally less to human nose-to-brain delivery.
No human pharmacokinetic study. There is no published study tracking labeled semax in human brain tissue after nasal delivery. The human evidence for brain effects (fMRI, EEG changes, cognitive outcomes) is indirect: it shows the brain responds, but it does not quantify how much semax is present in which brain regions at what concentrations.
Formulation variables. The studies used simple aqueous solutions. Modern nose-to-brain delivery research uses nanoparticles, mucoadhesive polymers, and cell-penetrating peptides to enhance brain penetration.[11] These technologies could potentially increase semax's already favorable brain delivery, but no such optimized formulation has been tested.
Degradation during transit. While 80% of brain radioactivity was intact semax, 20% was metabolites. The functional significance of this metabolite fraction is unclear. Pro-Gly-Pro may have its own activity, or it may be inert. This ambiguity makes it difficult to attribute brain effects entirely to intact semax versus its metabolic products.
Where Semax Fits in the Broader Nose-to-Brain Field
Semax is one of the earliest and most-studied examples of a peptide specifically designed for intranasal brain delivery. The broader field has since expanded to include hundreds of peptide candidates being developed for nose-to-brain administration.
Alabsi and colleagues (2022) reviewed the current landscape of nose-to-brain peptide delivery, cataloging the formulation strategies, nanocarrier technologies, and peptide modifications being explored to improve brain penetration.[1] Semax's Pro-Gly-Pro stabilization strategy was an early version of what has since become a sophisticated toolkit including PEGylation, cyclization, D-amino acid substitution, and cell-penetrating peptide conjugation.
Samaridou and Alonso (2018) specifically reviewed nanotechnology approaches to nose-to-brain peptide delivery, noting that while the field has advanced rapidly in formulation science, semax and a handful of other peptides remain the only ones with both clinical approval (in Russia) and published brain penetration data.[3]
The copper-binding properties of semax, documented by Tabbi and colleagues (2015), add another dimension. Semax binds copper(II) ions with high affinity, and copper dysregulation is implicated in neurodegenerative diseases.[12] Whether intranasal semax's copper-binding capacity contributes to its neuroprotective effects in the brain remains an open question.
The Bottom Line
Semax reaches the brain through direct olfactory and trigeminal nerve pathways when administered as a nasal spray, achieving roughly 9x greater brain penetration than intravenous delivery in rat studies. The peptide's Pro-Gly-Pro tail provides enzymatic stability, with 80% arriving in brain tissue intact. Human neuroimaging confirms brain-level effects after nasal delivery, though quantitative human pharmacokinetics have not been published. The data positions semax as one of the best-characterized nose-to-brain peptides, though the evidence base remains predominantly Russian and the field has advanced considerably in delivery technology since semax's original formulation.